Entering text into the input field will update the search result below

Dentsply Sirona: The Rebuilding Begins

Stephen Simpson profile picture
Stephen Simpson


  • Dentsply Sirona has a new management team in place and more details on how they intend to improve operating results should be coming fairly soon.
  • This business seems ripe for a portfolio review to pare out low-return/low-potential products and a restructuring of the global sales effort.
  • Market segments like imaging (intraoral scanning and standalone digital impressions), implants, biomaterials, and clear aligners can support a mid-single-digit revenue growth base.
  • I believe today's price reflects only modest improvement in Dentsply's operations; if management is willing to be bold and can execute on that vision, meaningful upside could come over time.

Modern dental drills and empty chair in the dentist"s office


Dental equipment and consumables manufacturer Dentsply Sirona (NASDAQ:XRAY) has recovered some stock price momentum over the past three months, outperforming the broader med-tech space, as well as peers/comps like Envista (NVST) and Straumann

This article was written by

Stephen Simpson profile picture
Stephen Simpson is a freelance financial writer and investor.Spent close to 15 years on the Street (sell-side, buy-side, equities, bonds).

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About XRAY

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on XRAY

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.